Chandra K. Singh, PhD
Ahmad Laboratory Page
All Inquiries: Research and Administration
BS (Chemistry, Botany, & Zoology) 1998, VBS Purvanchal University, India
MS (Bioetechnology) 2002, University of Jammu, India
PhD (Biochemistry) 2008, University of Lucknow, India
2003-2008: Research Fellow, Food and Toxicology Division, Indian Institute of Toxicology Research (IITR), Lucknow, India
2008-2011: Post-doctoral Research Fellow, Dept. of Pathology, Microbiology, & Immunology, University of South Carolina, USA
My research interests lie in the field of biomedical research specifically focuses on (a) chemoprevention and experimental therapeutics, and (b) identification of molecular targets for intervention. My long-term research goal is to define the critical molecular and biochemical events as well as fundamental cancer driver pathways in the process of cancer development and progression that will help us to identify the targets for disease management.
Using natural resources and cutting-edge scientific knowledge, I want to identify and develop new molecules, approaches, and strategies that can ultimately be translated from the bench to the bedside for the prevention and/or treatment of cancer, specifically for skin and prostate cancer.
Chhabra G, Singh CK, Ndiaye MA, Fedorowicz S, Molot A, Ahmad N. Prostate cancer chemoprevention by natural agents: clinical evidence and potential implications. Cancer Lett. 2018; 422:9-18. PMID: 29471004. IF 6.4
Singh CK, Chhabra G, Ndiaye MA, Garcia-Peterson LM, Mack NJ, Ahmad N. The Role of Sirtuins in Antioxidant and Redox Signaling. Antioxid Redox Signal. 2018; 28(8):643-661 PMID: 28891317. IF 7.1
Gutteridge RE*, Singh CK*, Ndiaye MA, Ahmad N. Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma. Cancer Lett. 2017, 394:13-21. PMID: 28235541. IF 6.4 (* Joint first author).
Seenivasan R, Singh CK, Warrick JW, Ahmad N, Gunasekaran S. Microfluidic-integrated patterned ITO immunosensor for rapid detection of prostate-specific membrane antigen biomarker in prostate cancer. Biosens Bioelectron. 2017, 95:160-167. PMID: 28445813. IF 7.5
Sanna V, Singh CK, Jashari R, Adhami VM, Chamcheu JC, Rady I, Sechi M, Mukhtar H, Siddiqui IA. Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy. Sci Rep. 2017; 7:41573. PMID: 28145499. IF 5.3.
Singh CK*, Malas KM, Tydrick C, Siddiqui IA, Iczkowski KA, Ahmad N. Analysis of zinc-exporters expression in prostate cancer. Sci Rep. 2016; 6:36772. PMID: 27833104. IF 5.3 (* Corresponding author).
Singh CK, Nihal M, Ahmad N. Histone Deacetylase Inhibitory Approaches for the Management of Osteoarthritis. Am J Pathol. 2016; 186(10):2555-8. Commentary. PMID: 27560709. IF 4.9
Singh CK, Siddiqui IA, El-Abd S, Mukhtar H, Ahmad N. Combination chemoprevention with grape antioxidants. Mol Nutr Food Res. 2016; 60(6):1406-15. Review. PMID: 26829056. IF 4.6
Singh CK, Xiaoqi Liu, Ahmad N. Resveratrol, in its natural combination in whole grape, for health promotion and disease management. Ann N Y Acad Sci. 2015, 1348(1):150-60. Review. PMID: 26099945. IF 4.4
Singh CK, Kaur S, George J, Nihal M, Pellitteri Hahn MC, Scarlett CO, Ahmad N: Molecular signatures of sanguinarine in human pancreatic cancer cells: A large scale label-free comparative proteomics approach. Oncotarget. 2015, 30;6(12):10335-49. IF 6.6